Idiopathic Pulmonary Fibrosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Idiopathic Pulmonary Fibrosis stocks.

Idiopathic Pulmonary Fibrosis Stocks Recent News

Date Stock Title
May 17 PULM Pulmatrix files for $95M mixed shelf
May 17 BIIB Ionis, Biogen Down on Ending Development of ALS Drug
May 17 BIIB Ionis (IONS), Biogen Down on Ending Development of ALS Drug
May 16 BIIB Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16 BIIB Biogen and Ionis drop ALS candidate after trial setback
May 16 BIIB Biogen, Ionis shelve ALS drug following study failure
May 16 BIIB REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
May 16 BIIB Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 BIIB Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 15 VCYT Veracyte to Participate in Upcoming Investor Conferences
May 15 BIIB Eisai projects major growth for Alzheimer's therapy Leqembi
May 15 BIIB Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
May 15 BIIB Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15 PULM Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
May 15 BIIB Eisai sets new revenue target for Alzheimer’s drug Leqembi
May 15 BIIB Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy
May 15 BIIB UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14 BIIB Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14 BIIB Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14 PLRX Pliant reports phase 2 data on idiopathic pulmonary fibrosis asset bexotegrast
Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired and nail clubbing. Complications may include pulmonary hypertension, heart failure, pneumonia, or pulmonary embolism.The cause is unknown. Risk factors include cigarette smoking, certain viral infections, and a family history of the condition. The underlying mechanism involves scarring of the lungs. Diagnosis requires ruling out other potential causes and may be supported by a CT scan or lung biopsy. It is a type of interstitial lung disease (ILD).People often benefit from pulmonary rehabilitation and supplemental oxygen. Certain medications like pirfenidone or nintedanib may slow the progression of the disease. Lung transplantation may also be an option.About 5 million people are affected globally. The disease newly occurs in about 12 per 100,000 people per year. Those in their 60s and 70s are most commonly affected. Males are affected more often than females. Average life expectancy following diagnosis is about four years.

Browse All Tags